Business Context and Reporting Period
Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter (Q2) and First Half (H1) ended June 30, 2024
Overview: GSK reported strong operational performance driven by broad-based sales growth across Vaccines, Specialty Medicines, and General Medicines. The company upgraded its full-year 2024 guidance for turnover, Core operating profit, and Core earnings per share (EPS). While Total operating profit and EPS declined due to significant non-cash charges related to contingent consideration liabilities (CCL) and foreign currency movements, Core metrics demonstrated robust underlying growth.
Key Financial Metrics
| Metric | Q2 2024 (£m) | Q2 2024 Growth (CER%) | H1 2024 (£m) | H1 2024 Growth (CER%) |
|---|---|---|---|---|
| Turnover | 7,884 | +13% | 15,247 | +12% |
| Total Operating Profit | 1,646 | -22% | 3,136 | -20% |
| Total Operating Margin | 20.9% | -9.1 ppts | 20.6% | -8.4 ppts |
| Total EPS | 28.8p | -27% | 54.5p | -24% |
| Core Operating Profit | 2,513 | +18% | 4,956 | +22% |
| Core Operating Margin | 31.9% | +1.3 ppts | 32.5% | +2.9 ppts |
| Core EPS | 43.4p | +13% | 86.5p | +20% |
| Cash Generated from Operations | 1,650 | +2% | 2,776 | +46% |
| Free Cash Flow | 328 | -6% | 617 | >100% |
| Net Debt | 13,960 | - | 13,960 | - |
Note: Growth percentages are at Constant Exchange Rates (CER) unless otherwise noted. Core results are non-IFRS measures excluding amortisation, restructuring, and other adjusting items.
Material Changes vs. Prior Period
- Revenue Growth: Total turnover increased 13% (CER) in Q2, driven by Specialty Medicines (+22%), General Medicines (+12%), and Vaccines (+1% ex-COVID). Oncology sales more than doubled to £0.4 billion.
- Profitability Divergence: Total operating profit fell 22% (CER) and Total EPS fell 27% (CER). This decline was primarily due to a £378 million charge for the remeasurement of contingent consideration liabilities (CCL) related to improved HIV prospects and foreign currency movements, alongside a fair value loss on the retained Haleon stake.
- Core Performance: Excluding adjusting items, Core operating profit grew 18% (CER) and Core EPS grew 13% (CER), reflecting strong sales leverage and favorable product mix.
- Product Specifics:
- Vaccines: Shingrix sales declined 4% (CER) in Q2 due to US channel inventory reductions and retail prioritization changes, though it grew significantly in International markets. Meningitis vaccines grew 24% (CER). Arexvy (RSV) sales were £62 million.
- Specialty Medicines: HIV sales grew 13% (CER), driven by long-acting medicines (Cabenuva, Apretude) and oral 2DR regimens (Dovato). Oncology sales surged due to Jemperli and Ojjaara/Omjjara.
- General Medicines: Trelegy sales grew 41% (CER). Performance was impacted by the removal of the Average Manufacturer Price (AMP) cap on Medicaid drug prices in the US, though this was offset by increased use of authorized generic versions.
- Balance Sheet: Net debt decreased to £13.96 billion from £15.04 billion at year-end 2023, aided by free cash inflow and proceeds from the disposal of the remaining Haleon stake.
Guidance, Outlook, and Risks
2024 Guidance Upgrade
GSK has upgraded its full-year 2024 guidance (at CER, excluding COVID-19 solutions):
- Turnover Growth: Increased to 7%–9% (previously 5%–7%).
- Core Operating Profit Growth: Increased to 11%–13% (previously 9%–11%).
- Core EPS Growth: Increased to 10%–12% (previously 8%–10%).
Dividend: A Q2 2024 dividend of 15p per share was declared. The full-year 2024 dividend is expected to be 60p per share.
Management Commentary
CEO Emma Walmsley highlighted "excellent second quarter performance" and "strengthening breadth of our portfolio." The company secured approvals or filings for 10 major opportunities in the first half of 2024 and reported positive data from 7 phase III trials. R&D investments continue to focus on mRNA vaccines, ultra-long-acting HIV medicines, and severe asthma treatments.
Risks and Contingencies
- Legal Matters (Zantac): Significant litigation continues regarding alleged cancer risks. A Delaware Superior Court decision allowed plaintiffs to present expert evidence on general causation. GSK cannot meaningfully assess potential liability at this stage.
- Contingent Consideration: Significant volatility in Total results is driven by fair value remeasurements of CCLs (primarily ViiV Healthcare and Novartis Vaccines), which are sensitive to sales forecasts and exchange rates.
- Regulatory/Market: Vaccine sales growth is impacted by revised US recommendations for RSV vaccinations. General Medicines face pricing pressures from US Medicaid policy changes.
Investor Verification Checklist
- CCL Sensitivity: Verify the impact of sales forecast changes and currency fluctuations on the £7.1 billion contingent consideration liability, which drives the divergence between Total and Core results.
- Shingrix Trajectory: Monitor US sales trends for Shingrix following channel inventory reductions and CMS reimbursement rule changes.
- Zantac Litigation: Track upcoming trial dates and Daubert motions in US state courts regarding product liability claims.
- Arexvy Adoption: Assess the impact of the US Advisory Committee on Immunization Practices (ACIP) recommendations on RSV vaccine uptake in the 50-59 age demographic.
- Core vs. Total Reconciliation: Review the reconciliation of Total to Core results to understand the magnitude of non-cash charges (amortization, restructuring, CCL remeasurement) affecting reported GAAP/IFRS profitability.